Technical Analysis for RLAY - Relay Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Historical RLAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.47% | |
| Crossed Above 20 DMA | Bullish | 2.47% | |
| MACD Bullish Signal Line Cross | Bullish | 2.47% | |
| Pocket Pivot | Bullish Swing Setup | 2.47% | |
| Volume Surge | Other | 2.47% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | 1 day ago | |
| Up 3% | 1 day ago | |
| 20 DMA Support | 1 day ago | |
| Down 3% | 1 day ago | |
| Down 2 % | 1 day ago |
Get a Trading Sidekick!
- Earnings date: ???
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 57.59 |
| 52 Week Low | 32.56 |
| Average Volume | 496,532 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 46.86 |
| 20-Day Moving Average | 43.42 |
| 10-Day Moving Average | 40.75 |
| Average True Range | 3.78 |
| ADX | 22.15 |
| +DI | 20.73 |
| -DI | 19.06 |
| Chandelier Exit (Long, 3 ATRs ) | 39.45 |
| Chandelier Exit (Short, 3 ATRs ) | 47.69 |
| Upper Bollinger Band | 50.58 |
| Lower Bollinger Band | 36.27 |
| Percent B (%b) | 0.6 |
| BandWidth | 32.95 |
| MACD Line | -1.47 |
| MACD Signal Line | -1.81 |
| MACD Histogram | 0.3424 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.34 | ||||
| Resistance 3 (R3) | 50.08 | 48.00 | 49.43 | ||
| Resistance 2 (R2) | 48.00 | 46.60 | 48.13 | 49.12 | |
| Resistance 1 (R1) | 46.42 | 45.73 | 47.21 | 46.68 | 48.81 |
| Pivot Point | 44.34 | 44.34 | 44.73 | 44.47 | 44.34 |
| Support 1 (S1) | 42.76 | 42.94 | 43.55 | 43.02 | 40.89 |
| Support 2 (S2) | 40.68 | 42.07 | 40.81 | 40.58 | |
| Support 3 (S3) | 39.10 | 40.68 | 40.28 | ||
| Support 4 (S4) | 39.36 |
